Effects of Lactobacillus plantarum Q180 on Postprandial Lipid Levels and Intestinal Environment: A Double-Blind, Randomized, Placebo-Controlled, Parallel Trial

Park, Ye Eun; Kim, Min Seo; Shim, Kyung Won; Kim, You Il; Chu, Jaeryang; Kim, Byoung Kook; Choi, In Suk; Kim, Ji Yeon

doi:10.3390/nu12010255

Cited by 22 publications

(25 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 12-week randomized, double-blind, placebo-controlled clinical trial has shown that the combination of three Lactobacillus plantarum strains can reduce blood cholesterol in patients ( Guerrero-Bonmatty et al., 2021 ). Additionally, a study involving 70 healthy adults has demonstrated that the daily supplementation of Lactobacillus plantarum Q180 can significantly improve blood-lipid indicators such as LDL-C and TC after meals by adjusting the composition of the intestinal flora ( Park et al., 2020 ). These studies reveal that probiotics can improve the level of TC, TG, HDL-C, and LDL-C by promoting the growth of probiotics, regulating related metabolites.…”

Section: Treatment Of Hyperlipidemia Targeted At Gut Microbiotamentioning

confidence: 99%

Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia

Jia

Zhang

et al. 2021

Front. Cell. Infect. Microbiol.

110

View full text Add to dashboard Cite

Hyperlipidemia, defined as the presence of excess fat or lipids in the blood, has been considered as a high-risk factor and key indicator of many metabolic diseases. The gut microbiota has been reported playing a vital role in regulating host lipid metabolism. The pathogenic role of gut microbiota in the development of hyperlipidemia has been revealed through fecal microbiota transplantation experiment to germ-free mice. The effector mechanism of microbiota-related metabolites such as bile acids, lipopolysaccharide, and short-chain fatty acids in the regulation of hyperlipidemia has been partially unveiled. Moreover, studies on gut-microbiota-targeted hyperlipidemia interventions, including the use of prebiotics, probiotics, fecal microbiota transplantation, and natural herbal medicines, also have shown their efficacy in the treatment of hyperlipidemia. In this review, we summarize the relationship between gut microbiota and hyperlipidemia, the impact of gut microbiota and microbiota-related metabolites on the development and progression of hyperlipidemia, and the potential therapeutic management of hyperlipidemia targeted at gut microbiota.

show abstract

Section: Treatment Of Hyperlipidemia Targeted At Gut Microbiotamentioning

confidence: 99%

Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia

Jia

Zhang

et al. 2021

Front. Cell. Infect. Microbiol.

110

View full text Add to dashboard Cite

show abstract

“…Heat-inactivated Lactobacillus plantarum L-137 reduced the levels of serum TC, LDL-C, AST, and ALT in overweight people ( 20 ). In a human clinical trial, treatment with live Lactobacillus plantarum Q180 for 12 weeks decreased postprandial maximum concentrations of TG, LDL-C, Apo B-100, and Apo B-48 levels ( 21 ).…”

Section: Introductionmentioning

confidence: 99%

Probiotic Effects of Lactobacillus fermentum ZJUIDS06 and Lactobacillus plantarum ZY08 on Hypercholesteremic Golden Hamsters

Yang

Lyu

et al. 2021

Front. Nutr.

View full text Add to dashboard Cite

Hypercholesteremia or high cholesterol is one of the important factors leading to atherosclerosis and other cardiovascular diseases. The application of probiotics with cholesterol-lowering characteristics has become increasingly popular over the past decade due to their contribution to human health. This study aimed to evaluate the probiotic effects of Lactobacillus fermentum ZJUIDS06 and Lactobacillus plantarum ZY08 on hyperlipidemic golden hamsters. A hyperlipidemic model was established through a high cholesterol diet in golden hamsters, after which lyophilized Lactobacillus fermentum ZJUIDS06 and Lactobacillus plantarum ZY08 were orally administered individually for 8 weeks. The physiological characteristics of golden hamsters and short chain fatty acid (SCFA) in the colon were assessed by automatic Biochemical Analyzer and gas choromatograph, respectively. A MiSeq sequencing-based analysis of the bacterial 16S rRNA gene (V3–V4 region) in the cecum content was performed to analyze the cecum microbiota. Correlations between sets of these variables were also investigated using the R package “corrplot.” Results showed that neither Lactobacillus fermentum ZJUIDS06 nor Lactobacillus plantarum ZY08 inhibited body weight increase. However, supplementation with Lactobacillus fermentum ZJUIDS06 for 8 weeks increased colon SCFA levels (P < 0.05), decreased serum low-density lipoprotein, total cholesterol, and triglycerides levels, and also induced changes in the cecum microbiota of hyperlipidemic golden hamsters. Remarkably, oral administration of Lactobacillus fermentum ZJUIDS06 increased the relative abundance of Parabacteroides in the cecum, which served as a biomarker for colon SCFA production and improvement of serum cholesterol levels. In a word, Lactobacillus fermentum ZJUIDS06 improved hyperlipidemia in golden hamsters, which correlated with an increase in SCFA levels and relative abundance of Parabacteroides, indicating its potential importance in functional foods that can help lower cholesterol.

show abstract

“…identified 12 double-blind, placebo-controlled, randomized trials that compared the changes in the gut microbiota after treatment with probiotics or placebo (Table 3b). [26][27][28][29][30][31][32][49][50][51][52] Most of these RCTs showed that there were no significant changes in α-diversity and β-diversity in the probiotic group compared to the placebo group. TA B L E 3 (Continued)…”

Section: The Impact Of Lactobacillus Acidophilus and Lactobacillus Rhamnosus On Fecal Microbiotamentioning

confidence: 99%

The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota—a double‐blind, placebo‐controlled, randomized trial

Chen

Huang

et al. 2021

Helicobacter

View full text Add to dashboard Cite

BackgroundProbiotics may alter the gut microbiota and may reduce antibiotic‐related dysbiosis after H. pylori eradication. However, whether probiotics are effective in reducing the bacterial load of H. pylori and modifying the gut microbiota remains unknown. We aimed to assess the efficacy of Lactobacillus acidophilus and Lactobacillus rhamnosus in reducing the bacterial load of H. pylori and modifying the gut microbiota.Materials and methodsIn this double‐blind, randomized, placebo‐controlled trial, we recruited 40 adult subjects with moderate to high bacterial loads of H. pylori, defined as a mean delta over baseline (DOB) value of the 13C‐urea breath test (13C‐UBT) of 10 or greater every 4 days 6 times. Eligible subjects were randomized in a 1:1 ratio to receive either probiotics containing Lactobacillus acidophilus and Lactobacillus rhamnosus or placebo twice daily for 4 weeks. 13C‐UBT was measured weekly from the beginning of treatment to 2 weeks after treatment. Amplification of the V3 and V4 hypervariable regions of the 16S rRNA was performed for fecal microbiota.ResultsA total of 40 subjects were randomized to receive probiotics or placebo. The DOB value was significantly lower in the probiotic group than in the placebo group after 4 weeks of treatment (26.0 vs. 18.5, p = .045). The DOB value was significantly reduced compared to that at baseline in the probiotic group (18.5 vs. 26.7, p = .001) but not in the placebo group (26.0 vs. 25.0, p = .648). However, the eradication rate for H. pylori was 0% in both groups. There was no significant difference in the DOB values between the two groups 1 and 2 weeks after discontinuation of the probiotics. There were also no significant changes observed in the α‐diversity and β‐diversity at week 4 compared to baseline in the probiotic group (p = .77 and 0.91) and the placebo group (p = .26 and 0.67).ConclusionsAlthough the use of Lactobacillus acidophilus and Lactobacillus rhamnosus may reduce the bacterial load of H. pylori, there were no significant changes in the composition of gut microbiota. This trial is registered with ClinicalTrials.gov, NCT02725138.

show abstract

Effects of Lactobacillus plantarum Q180 on Postprandial Lipid Levels and Intestinal Environment: A Double-Blind, Randomized, Placebo-Controlled, Parallel Trial

Cited by 22 publications

References 51 publications

Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia

Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia

Probiotic Effects of Lactobacillus fermentum ZJUIDS06 and Lactobacillus plantarum ZY08 on Hypercholesteremic Golden Hamsters

The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota—a double‐blind, placebo‐controlled, randomized trial

Contact Info

Product

Resources

About